A Phase II Evaluation of Pazopanib in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
Latest Information Update: 27 Aug 2023
At a glance
- Drugs Pazopanib (Primary)
- Indications Leiomyosarcoma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 17 Nov 2015 Status changed from not yet recruiting to withdrawn prior to enrolment.as reported by ClinicalTrials.gov record.
- 09 Mar 2015 New trial record